« Back
Home /
Anti-Human TRAIL R4 (Internal Domain) - 0.1 mg

Anti-Human TRAIL R4 (Internal Domain) - 0.1 mg

Item no.	LEIN-D248-0.1mg
Manufacturer	Leinco Technologies
Amount	0.1 mg
Quantity options	0.1 mg 0.5 mg 1 mg 20 ug
Category	Oncology Neuroscience Neuroinflammation Metabolism Diabetes Antibodies By Cell Type Cell Biology Obesity Cell Culture Cytokines Cell Status Necrosis Apoptosis Immunohistochemistry Western Blot Primary Antibodies
Type	Antibody Primary
Applications	WB, IHC
Specific against	Human (Homo sapiens)
Host	Rabbit
Citations	1. Chan, FK. et al. (2005) Proc Natl Acad Sci USA 102: 18099 2. Sanlioglu, S. et al. (2005) BMC Cancer 5: 54
ECLASS 10.1	32160702
ECLASS 11.0	32160702
UNSPSC	12352203
Shipping Condition	Room temperature
Available
Manufacturer - Applications	IHC FFPE, WB
Manufacturer - Category	Primary Monoclonal Antibodies>Apoptosis & Cell Biology
Manufacturer - Targets	TNF-Related Apoptosis-Inducing Ligand Receptor 4
Country of Origin	USA
Shipping Temperature	Next Day Ambient
Storage Conditions	This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage, aliquot in working volumes without diluting and store at –20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Product Description	TNF-related apoptosis-inducing ligand receptor 4 (TRAIL R4) is a decoy receptor that negatively regulate TRAIL-induced cytotoxicity by competing for ligand binding with TRAIL-R1 and TRAIL-R2.1 TRAIL R4 is expressed mainly on CD8+ and NK cells and induces apoptosis in many tumour cells, but not in normal cells. TRAIL-R4 contains partially truncated death domain and therefore is unable to induce apoptosis and serves as a negative regulator of apoptotic signaling by impairment death-inducing signaling complex (DISC) processing.1, 2
Background	TNF-related apoptosis-inducing ligand receptor 4 (TRAIL R4) is a decoy receptor that negatively regulate TRAIL-induced cytotoxicity by competing for ligand binding with TRAIL-R1 and TRAIL-R2.¹ TRAIL R4 is expressed mainly on CD8+ and NK cells and induces apoptosis in many tumour cells, but not in normal cells. TRAIL-R4 contains partially truncated death domain and therefore is unable to induce apoptosis and serves as a negative regulator of apoptotic signaling by impairment death-inducing signaling complex (DISC) processing.^{1, 2}
PubMed	TNF-Related Apoptosis-Inducing Ligand Receptor 4
Manufacturer - Specificity	Rabbit Anti-Human TNF-Related Apoptosis-Inducing Ligand Receptor 4 (TRAIL R4) recognizes Human TRAIL R4. This polyclonal antibody was purified using affinity chromatography.
RRID	AB_2829902
Concentration	0.5 mg/ml
Formulation	This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Immunogen	PN:D266
Additional Information	Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
Keywords	Polyclonal Antibody, TNF-Related Apoptosis-Inducing Ligand Receptor 4, TNFRSF10D, Decoy Receptor 2 (DCR2), CD264, TRUNDD, TR4, TRAIL R4, Human, Anti-Human TRAIL R4 (Internal Domain)

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

LEIN-D248-0.1mg-safety-datasheet.pdf